Johnson & Johnson: raises forecasts after 'solid' quarter
(CercleFinance.com) - Johnson & Johnson on Tuesday raised its full-year 2019 sales forecasts after reporting quarterly results that beat expectations, helped by strength in its pharmaceuticals business.
The US healthcare giant raised its 2019 operational sales forecast to a range of 82.4 billion to 83.2 billion dollars, from 82 billion to 82.8 billion dollars previously.
Its EPS guidance range remained unchanged, though.
For the second quarter, net earnings fell to 5.6 billion dollars, or 2.08 dollar per share, from 3.9 billion dollars, or 1.45 dollar per share. Total revenue fell 1.3 percent to 20.6 billion dollars.
Pharmaceutical operational sales grew 4.4%, driven by the company's treatments against multiple myeloma, inflammatory diseases, cancers and antipsychotics.
Shares of the diversified healthcare products maker rose 0.4 percent in pre-market trading on the New York Stock Exchange.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The US healthcare giant raised its 2019 operational sales forecast to a range of 82.4 billion to 83.2 billion dollars, from 82 billion to 82.8 billion dollars previously.
Its EPS guidance range remained unchanged, though.
For the second quarter, net earnings fell to 5.6 billion dollars, or 2.08 dollar per share, from 3.9 billion dollars, or 1.45 dollar per share. Total revenue fell 1.3 percent to 20.6 billion dollars.
Pharmaceutical operational sales grew 4.4%, driven by the company's treatments against multiple myeloma, inflammatory diseases, cancers and antipsychotics.
Shares of the diversified healthcare products maker rose 0.4 percent in pre-market trading on the New York Stock Exchange.
Copyright (c) 2019 CercleFinance.com. All rights reserved.